GLA and Fabry disease: In this study, we evaluated a cohort of 102 genetically confirmed female FD patients from six Fabry centers (five German centers, one Swiss center) with well-characterized clinical phenotypes at three time points to assess the impact of agalsidase-alfa, agalsidase-beta and migalastat in newly- as well as long-term-treated patients.